Merck and Ridgeback Biotherapeutics Begin P-III (MOVe-NOW) Trial of Lagevrio (Molnupiravir) to Treat COVID-19 in High-Risk Adults
Shots:
- The P-III (MOVe-NOW) trial will assess Lagevrio (800mg, oral, Q12H, for 5 days) vs PBO in non-hospitalized COVID-19 adults (n= ~3,082; ≥18yrs.), at high progression risk & ineligible for nirmatrelvir/ritonavir. It also includes 5.5mos. follow-up to find post-acute sequelae of COVID-19 (PASC) at Days 29, 56, 112, and 168
- Efficacy & safety 1EPs include patient proportion who were hospitalized or died due to any reason or had a COVID-19-associated medical visits at D29, AEs & related treatment discontinuations
- 2EPs are sustained COVID-19 symptom relief without relapse, SARS-CoV-2 viral load assessment, time to sustained symptom resolution & rates of medical interventions, hospitalization or death by D29
Ref: Merck | Image: Merck
Related News:- Merck’s Sacituzumab Tirumotecan (Sac-TMT) Secures the US FDA’s Breakthrough Therapy Designation to Treat Non-Squamous NSCLC
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
